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Abstract
Radiation resistance and toxicity in normal tissues are limiting factors in the efﬁcacy of
radiotherapy. Gold nanoparticles (GNPs) have been shown to be effective at enhancing
radiation-induced cell death, and were initially proposed to physically enhance the radiation dose
deposited. However, biological responses of GNP radiosensitization based on physical
assumptions alone are not predictive of radiosensitisation and therefore there is a fundamental
research need to determine biological mechanisms of response to GNPs alone and in
combination with ionising radiation. This study aimed to identify novel mechanisms of cancer
cell radiosensitisation through the use of GNPs, focusing on their ability to induce cellular
oxidative stress and disrupt mitochondrial function. Using N-acetyl-cysteine, we found
mitochondrial oxidation to be a key event prior to radiation for the radiosensitisation of cancer
cells and suggests the overall cellular effects of GNP radiosensitisation are a result of their
interaction with protein disulphide isomerase (PDI). This investigation identiﬁes PDI and
mitochondrial oxidation as novel targets for radiosensitisation.
S Online supplementary data available from stacks.iop.org/NANO/27/215101/mmedia
Keywords: nanoparticle, bioactivity, thiol, oxidation
(Some ﬁgures may appear in colour only in the online journal)
Introduction
Radiotherapy aims to maximise the differential between
radiation dose deposited in the tumour whilst minimising the
dose to the surrounding normal tissue. Although clinical
delivery methods such as IMRT and hadron therapy have
signiﬁcantly improved conformity to the tumour target, the
potential for radiation sensitisers to increase the therapeutic
index of radiotherapy remains to be developed.
One of the main challenges in radiotherapy and tumour
imaging is the lack of contrast between the radiation
absorption properties of normal tissue and cancerous tissue
making normal tissue tolerance the limiting dose factor in the
delivery of radiotherapy [1]. Creating a contrast between
these two tissues would reduce the size of the delivered dose
outside the target, sparing normal tissue toxicity, whilst
achieving the effects of a higher dose in the cancerous tissue.
High Z (atomic number) materials such as gadolinium, iodine
and gold to name a few, have the potential to physically
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enhance the local dose deposited by the radiation beam as a
result of favourable mass attenuation coefﬁcients [2]. An
enhanced contrast between two materials resulting in addi-
tional energy deposition was ﬁrst demonstrated by Spiers in
1949 when he investigated why tolerances of soft tissue to
radiation was dependent on its vicinity to bone [3].
Considering atomic number, gold is an obvious candidate
as a contrast agent and radiation modiﬁer. In the form of
nanoparticles, gold has a range of potential properties for use
in cancer therapy is signiﬁcantly enhanced with the ability to
speciﬁcally target GNPs to tumour cells while delivering anti-
cancer drugs. High Z number materials are characterised by
the large numbers of electrons in with high photoelectric
cross-sections, resulting in high mass attenuation coefﬁcients.
As a result, high Z materials have the potential to physically
enhance the local dose deposited by the radiation beam. High
Z materials such as iodine have been used as imaging contrast
agents for decades, although early studies showed in vitro that
these agents are capable of causing additional cell damage
following irradiation [4, 5]. Recent in vivo studies have
observed evidence of increased damage when these agents are
present during imaging [6–8]. Although safer contrast agents
would be beneﬁcial, in cancer treatment it is anticipated that
the conventionally undesirable effects of these contrast agents
can be taken advantage of to improve tumour cell killing.
Gold nanoparticles (GNPs) and nanotechnology are not
new concepts but their applications in biology and particu-
larly medicine offer innovative options for future applica-
tions. In particular, their potential for use in cancer therapy
offers a multi-use treatment which could enhance tumour
imaging and cancer cell targeting as well as cancer drug
delivery. GNPs have been shown to target tumour cells pas-
sively as well as having the potential to be modiﬁed with
targeting molecules such as antibodies to actively target
tumour cells [9]. In passive targeting, the GNPs take advan-
tage of the enhanced permeability and retention effect which
allows them to migrate through the leaky vasculature culti-
vated by tumour cells and thereby preferentially accumulate at
tumour sites [10]. Alternatively GNPs can be conjugated with
a targeting molecule, typically an antibody, which can detect
a tumour speciﬁc molecule which is overexpressed on the
tumour cell such as EGFR, and ideally this targeted molecule
should be vital for cellular function [10, 11].
We have previously calculated that a 1% weight for
weight concentration of gold would double the absorbed dose
at kilovoltage energies [1]. Calculations have predicted dose
enhancement factors (DEFs) of between 1.2 and 5 when using
GNPs in combination with radiation depending on the
quantity of gold present and the energy of the beam used
[12, 13]. These studies suggest that dose enhancement is most
achievable in the kilovoltage energy range due to the strong
contrast between soft tissue and GNPs in this energy region
[13, 14]. By contrast, their similar absorption at megavoltage
energies leads to limited contrast in higher energy exposures.
Most clinical radiotherapy equipment operates outside the
predicted optimal range, using megavoltage energies with
ﬁlters to reduce the low energy (keV) component.
Despite these predictions radiosensitization has been
shown in cells exposed to GNPs and irradiated with mega-
voltage energies, and at concentrations signiﬁcantly below the
1% mass suggested by theoretical predictions [15, 16]. While
radiosensitization observed at these higher energies can be
partly explained by considering the shower spectrum pro-
duced in the sample and the interaction of the daughter par-
ticles with the nanoparticles [17], there remains the possibility
of additional, perhaps biological, processes in the radio-
sensitising effect of GNPs. This was highlighted in a recent
review by Butterworth et al who concluded that the physical
dose deposition model did not accurately reﬂect or explain the
observed experimental outcomes of GNPs with radiation in
cellular systems [2]. Numerous potential mechanisms were
identiﬁed, including increased cellular oxidative stress,
impacts on cell cycling or DNA repair, and issues around
nanoparticle toxicity.
A large number of studies have sought to determine
mechanisms of cellular responses to GNPs whilst compara-
tively few have investigated biological sensitisation effects of
GNPs in combination with irradiation. Several previous
reports from our group have focussed on the commercially
available 1.9 nm AurovistTM GNP (Nanoprobes Inc.) [15, 18–
20]. This study aimed to further these previously published
studies in order to determine the biological effects of these
nanoparticles and elucidate the mechanism of GNP radio-
sensitization. We have already shown radiosensitisation, an
oxidative stress response as well as DNA damage in cells
after treatment with these GNPs. This paper furthers this
previous research by linking the observed effects and identi-
fying a novel biological mechanism which is a signiﬁcant
driver for the observed radiosensitisation of cancer cells by
these widely studied GNPs.
Materials and methods
Cell culture
All cell lines were obtained from Cancer Research UK. The
human breast cancer cell line, MDA-MB-231 was maintained
in Dulbecco’s modiﬁed Eagle’s medium supplemented with
10% foetal bovine serum and 1% penicillin/streptomycin.
The human prostate cell line, DU-145 was maintained in
RPMI-1640 medium with 10% foetal bovine serum and 1%
penicillin/streptomycin. The human glioma cell line, T98G
was maintained in Eagle’s minimum essential media supple-
mented with 10% foetal bovine serum and 1% penicillin/
streptomycin. All cells were grown at 37 °C in a humidiﬁed
atmosphere of 95% air/5% CO2. N-acetyl-Cysteine (catalo-
gue no. 7250, Sigma-Aldrich, St Louis, MO) was dissolved in
H20 and neutralised. Cells were treated at a concentration of
5 mM for 2 h prior to or after GNP incubation. Bacitracin
(catalogue no. B0125, Sigma-Adlrich) was dissolved in H2O
and cells were treated at 3 mM for 2 h (prior to incubation
with GNPs. AurovistTM 1.9 nm GNPs were purchased from
Nanoprobes Inc. (NY) and resuspended in H2O. Cells were
2
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treated at a concentration of 500 μg ml−1 for 24 h unless
otherwise indicated.
Detection of reactive oxygen species (ROS)
Cells were seeded into 12 well plates at a density of 1×105
cells per well and left to attach for 4–6 h before being treated
accordingly. ROS were measured using Carboxy-H2DCFDA
(Invitrogen Life Technologies, cat no. C13293) at a con-
centration of 5 μM. Cells were incubated with the dye in
serum free Optimem Media (Invitrogen Life Technologies)
for 45 min, then cells were allowed to recover for 30 min in
normal serum media, 2.5 mM hydrogen peroxide was added
to positive control cells at this stage. Cell media was collected
and placed in 15 ml centrifuge tubes while cells were
detached using 0.1% EDTA in PBS and added to the col-
lected media. Cells were then pelleted by centrifugation at
2000 rpm at 4 °C for 5 min. Media was removed and cell
pellets were suspended in PBS and analysed immediately
using a FACSCalibur ﬂow cytometer and CELL-Quest soft-
ware (Becton-Dickson). 1×104 cells were analysed per
sample.
Mitochondrial oxidation detection
Mitochondrial oxidation was measured using Nonyl-Acridine
Orange (NAO) (cat no A-1372, Molecular Probes, Invitrogen,
NY). 1×105 cells were seeded into 12 well plates and left to
attach for 4–6 h before being treated accordingly. At the end
of treatment, media was removed from cells and transferred to
15 ml centrifuge tubes on ice. Cells were detached using
0.25% Tryspin/1 mM EDTA solution and added to corresp-
onding tubes containing media. Cells were then pelleted by
centrifugation at 2000 rpm at 4 °C for 5 min. Media was
removed and cell pellets were resuspended in 300 μl of 0.1%
BSA-PBS solution containing 25 ng ml−1 NAO and left to
incubate at 37° for 10 min. Cells were placed on ice post-
incubation and analysed immediately using FACSCalibur
ﬂow cytometer and CELL-Quest software (Becton-Dickson).
1×104 cells were analysed per sample.
Mitochondrial membrane polarisation measurement
Cells were seeded into 12 well plates at a density of 1×105
cells per well and left to attach for 4–6 h before being treated
accordingly. 25 nM Tetramethylrhodamine ethyl ester per-
chlorate (TMRE) (Sigma-Aldrich) was added to each well
and incubated for 15 min at 37 °C. Media was then transferred
to 15 ml centrifuge tubes and placed on ice. Cells were
detached using 0.25% trypsin and 1 mM EDTA and the cell
solution was then transferred to the corresponding 15 ml tube
left on ice. Cells were then pelleted by centrifugation at
2000 rpm at 4 °C for 5 min. Media was removed and cell
pellets were resuspended in 300 μl of PBS and TMRE
ﬂuorescence was analysed immediately using a FACSCalibur
ﬂow cytometer and CELL-Quest software (Becton-Dickson).
1×104 cells were analysed per sample.
Clonogenic cell survival assay
Sub-conﬂuent cells were removed from ﬂasks using a solution
of 0.25% Trypsin and 1 mM EDTA, they were counted using
a coulter counted and re-seeded into six well plates at a
density of 1.5×105 cells per well. Cells were left to attach
for 4–6 h and were then treated with GNPs for 24 h. Cells
were then irradiated, trypsinised and counted, then seeded
into T25 ﬂasks using appropriate cell numbers and left to
proliferate for 7–9 d.
Statistical analysis
Cell survival data was ﬁtted with a linear quadratic trend,
= a b- -S e ,D D2 where α and β are radiosensitivity parameters
and D is the delivered dose and ﬁtted using the nonlinear
regression function in Prism version 4.01 (Graphpad Software
Inc.). DEF is deﬁned here as the ratio of doses which lead to
equal levels of cell survival with and without GNPs. DEFs
can vary with delivered dose, and are quoted with reference to
the dose delivered to cells in the absence of GNPs. Statisti-
cally signiﬁcant differences were calculated using the two
tailed paired t-test function in Prism version 4.01 with a p
value of 0.05 considered as signiﬁcant.
Results
Cellular effects of GNP treatment
MDA-MB-231, DU145 and T98G cells were treated with
1.9 nm GNPs at a concentration of 500 μg ml−1 for time
intervals ranging from 1 to 24 h. This nanoparticles, the
concentration, these time-points and the cell lines were cho-
sen as a result of previous work within the group showing that
500 μg ml−1 for 24 h allows for maximal cell uptake [15].
Preliminary data were also obtained with a 15 nm GNP from
Nanoprobes, however no signiﬁcant sensitisation was
observed in these particles (supplementary ﬁgure 1). This
absence of an effect is believed to be the result of their dif-
ferent surface functionalization to the 1.9 nm GNPs, and so
these particles were not taken forward to subsequent experi-
ments. The cell lines used represent tumours from different
sites of the body with varying degrees of radiosensitivity.
1.9 nm GNP radiosensitisation was also tested in normal
human ﬁbroblast cells, AGO-1522b, but no radiosensitisation
was observed (supplementary ﬁgure 2). At each time-point,
levels of ROS, mitochondrial polarisation and mitochondrial
oxidation were measured post incubation (ﬁgure 1). All cell
lines responded with a 2 to 3 fold increase in ROS levels from
the 1 h time-point which were maintained until the 24 h time-
point in both MDA-MB-231 and DU145 cell lines, however
only the 1 and 24 h increases in ROS in the MDA-MB-231
cells were signiﬁcant (ﬁgure 1(A)). A trend for increased ROS
of up to 5 fold was observed in T98G cells at the 1, 3 and 24 h
time-points with the 6 h time-point showing ROS levels clo-
ser to those seen in the control cells.
Mitochondrial membrane polarisation was assessed by
measuring the retention of tetramethylrhodamine ethyl ester
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perchlorate (TMRE) dye using ﬂow cytometry. TMRE is
preferentially taken up by functional, polarised, negatively
charged mitochondria causing cells to ﬂuoresce red. In
response to stress, mitochondria lose membrane potential and
become fully permeable meaning the dye is no longer retained
and ﬂuorescence is lost. The effect of GNP exposure on
mitochondrial membrane polarisation in MDA-MB-231,
DU145 and T98G cells was assessed using TMRE and ﬂow
cytometry at 1, 3, 6 and 24 h time-points (ﬁgure 1(B)). The
loss of TMRE ﬂuorescence across all cell lines from as soon
as 1 h exposure to 1.9 nm GNP indicates mitochondrial stress
as a rapid response to GNP contact. Fluorescence is sig-
niﬁcantly reduced to 63% of control in MDA-MB-231 cells
but non-signiﬁcantly reduced to 63% and 78% in DU145 and
T98G cells after 1 h exposure to 1.9 nm GNPs. These levels
of ﬂuorescence remain consistent in MDA-MB-231 and
T98G cells throughout the time course with a further drop in
ﬂuorescence to 34% at 24 h in MDA-MB-231 cells. Mito-
chondrial polarisation appears to ﬂuctuate throughout the time
course in DU145 cells with some apparent recovery in
polarity at 6 h when TMRE ﬂuorescence increases to 79%,
however, at 24 h it has signiﬁcantly reduced again to 54% of
the control.
Levels of mitochondrial oxidation were evaluated using
nonyl-acridine orange (NAO), a ﬂuorescent dye with an
afﬁnity for cardiolipin; a lipid found in the inner mitochon-
drial membrane. Upon mitochondrial oxidation, this lipid is
oxidised and NAO can no longer bind, thereby ﬂuorescence is
lost. Mitochondrial oxidation was measured after 1, 3, 6 and
24 h incubations with GNPs in MDA-MB-231, DU145 and
T98G cells (ﬁgure 1(C)). After 1 h treatment with 1.9 nm
GNPs, MDA-MB-231 and T98G cells undergo signiﬁcant
mitochondrial oxidation with a reduction in ﬂuorescence of
32% and 10% from controls respectively. Both cell lines
Figure 1. (A) Reactive oxygen species with GNP treatment. Carboxy-H2DCFDA was used to measure reactive oxygen species levels relative
to untreated control using ﬂow cytometry after cells were treated with 1.9 nm GNPs for indicated time points. Cells were treated with 2.5 mM
H2O2 for 30 min as a positive control. n=4. (B) Mitochondrial polarisation after GNP treatment. Mitochondrial polarisation was measured
in MDA-MB-231, DU145 and T98G cells by TMRE ﬂuorescent ﬂow cytometry relative to untreated controls after cells were treated with
1.9 nm GNPs for indicated time points. Cells were treated with 2.5 mM H2O2 for 30 min as a negative control. n=4. (C) Mitochondrial
oxidation after GNP treatment. Mitochondrial oxidation as measured by Nonyl Acridine Orange ﬂow cytometry relative to untreated control
after cells were treated with 1.9 nm GNPs for indicated timepoints. Cells were treated with 2.5 mM H2O2 for 30 min as a positive control.
n=4. Means are presented±standard error of the mean. Signiﬁcance was measured by paired t tests against controls.*p=0.05,
**p=0.01, ***p=0.001.
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continue to undergo mitochondrial oxidation for the duration
of the time course with a reduction in ﬂuorescence of 47% in
MDA-MB-231 cells and 40% in T98G cells at 24 h. DU145
cells however, do not undergo signiﬁcant mitochondrial
oxidation until 24 h GNP exposure with a signiﬁcant reduc-
tion in ﬂuorescence of 28%.
Cellular GNP uptake was also measured by inductively
coupled plasmon mass spectrometry for this treatment time
course (supplementary ﬁgure 3(A)). MDA-MB-231 and
T98G cells showed similar GNP uptake with an increased in
GNPs per cell as the time course elapsed. DU145 cells
showed fewer GNPs per cell than MDA-MB-231 and T98G
cells, but a similar increase in uptake as the time course
progressed.
The impact of oxidative stress on cell survival post irradiation
In order to determine what impact, if any, this oxidative stress
has on overall cell survival post irradiation with GNPs we
used the antioxidant NAC to abrogate the oxidative stress.
However, we found that the NAC was ineffective at pre-
venting GNP-induced ROS levels at the point of radiation
(24 h after NAC treatment)(supplementary ﬁgure 4(A)).
Despite the presence of ROS with the NAC/1.9 nm combi-
nation treatment, mitochondrial polarisation was restored to
near control levels across all cell lines (supplementary ﬁgure
4(B)) and NAC also prevented GNP-induced mitochondrial
oxidation in certain treatment combinations in DU145 and
T98G cells (ﬁgure 2(B)).
Clonogenic cell survival assays were then performed to
determine the effect of these events on overall cell survival
post irradiation (ﬁgure 2(A)). The DEFs for these treatments
are presented in table 1 alongside values corrected for the
effects of NAC and irradiation alone. In MDA-MB-231 cells,
the radiosensitising effect of 1.9 nm GNPs can be completely
abrogated by treatment with NAC either prior to GNP
exposure (NAC/1.9 nm) or post GNP exposure (1.9 nm/
NAC) with DEFs at 2 Gy of 1.52±0.03 with 1.9 nm GNPS
alone, 1.01±0.01 with NAC treatment prior to GNP expo-
sure and 0.97±0.02 with GNP exposure then NAC treat-
ment. NAC treatment prior to GNP exposure also abrogated
the radiosensitising effects of GNPs in T98G cells with a
reduction in DEF at 2 Gy from 1.92±0.05 with GNPs to
0.82±0.05 with NAC followed by GNP treatment. In
DU145 cells the radiosensitising effect is unaltered by NAC
treatment prior to GNP exposure as signiﬁcant radio-
sensitization still occurs with a DEF at 2 Gy of 2.02±0.01.
Alternatively, treating DU145 cells with NAC post GNP
exposure and prior to irradiation signiﬁcantly protects against
the radiosensitising effects of 1.9 nm GNPs reducing the DEF
at 2 Gy from 1.82±0.01 with GNPs alone to 1.33±0.04
with GNPs then NAC. This protective effect becomes more
prominent in DU145 cells with increasing dose with a DEF of
1.05±0.01 at 8 Gy. Radiosensitization in T98G cells is also
greatly reduced but not removed with DEF at 2 Gy of
1.15±0.04.
In order to ensure the observed effects were a result of
the impact of NAC on biological mechanisms and not on cell
uptake of GNPs, cellular GNP content after NAC and/or
GNP treatment was measured by inductively coupled plas-
mon mass spectrometry (supplementary ﬁgure 3(B)). It was
found that treating with NAC before or after 1.9 nm exposure
did not signiﬁcantly decrease GNP cellular content and in fact
Figure 2. (A) Clonogenic cell survival curve with NAC and 1.9 nm GNPs. Cell survival following treatment with different combinations of
anti-oxidant NAC and 1.9 nm gold nanoparticles along with irradiation. NAC/1.9 nm indicates cells were treated with 5 mM NAC for 2 h
prior to 500 μg ml−1 1.9 nm GNPs for 24 h and then irradiated. 1.9 nm/NAC inidicates cells were treated for 24 h 500 μg ml−1 1.9 nm
GNPS prior to 2 h 5 mM NAC treatment and then irradiated. Means are presented±standard error of the mean. n=5. (B) Mitochondrial
oxidation after treatment with ROS scavenger. Mitochondrial oxidation as measured by Nonyl Acridine Orange ﬂow cytometry relative to
untreated control after cells were treated with an ROS scavenger (NAC) prior to or after 1.9 nm GNP exposure for 24 h. Means are
presented±standard error of the mean. n=4. Signiﬁcance was measured by paired t tests. *= p0.05.
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Table 1. Dose enhancement factors. Table of DEFs with errors for cells treated with NAC and/or 1.9 nm GNPs at 2, 4 and 8 Gy. Numbers in bold italics are corrected for effect of NAC with
radiation.
MDA-MB-231 DU145 T98G
2 Gy 4 Gy 8 Gy 2 Gy 4 Gy 8 Gy 2 Gy 4 Gy 8 Gy
NAC 1.23±0.01 1.24±0.01 1.05±0.01 0.81±0.03 0.90±0.01 1.02±0.01 1.31±0.05 1.12±0.02 0.99±0.01
NAC—1.9 nm 1.25±0.01 1.19±0.01 1.17±0.01 1.64±0.01 1.44±0.01 1.28±0.1 1.08±0.05 1.12±0.02 1.15±0.01
1.01 ± 0.01 0.96 ± 0.01 1.11 ± 0.01 2.02 ± 0.03 1.60 ± 0.01 1.25 ± 0.01 0.82 ± 0.07 1.00 ± 0.03 1.16 ± 0.01
1.9 nm—NAC 1.19±0.02 1.14±0.01 1.10±0.01 1.08±0.03 1.08±0.01 1.07±0.01 1.50±0.04 1.19±0.01 1.07±0.01
0.97 ± 0.02 0.92 ± 0.01 1.05 ± 0.01 1.33 ± 0.04 1.20 ± 0.03 1.05 ± 0.03 1.15 ± 0.06 1.06 ± 0.03 1.08 ± 0.04
1.9 nm 1.52±0.03 1.27±0.01 1.14±0.01 1.82±0.01 1.59±0.01 1.36±0.01 1.92±0.05 1.53±0.01 1.33±0.01
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resulted in signiﬁcantly greater GNPs per cell in DU145 cells
especially in the NAC pre-treated cells.
The role of protein disulphide isomerase (PDI)
Given the oxidative stress cell response upon treatment with
GNPs and the knowledge that the GNPs are thiol-coated,
(PDI) was identiﬁed as a potential mediator of the overall
cellular response to GNPs. The enzymatic action of PDI is
blocked by the antibiotic, bacitracin which has been shown to
be a speciﬁc inhibitor of the reductive activity of PDI [21].
Having established that bacitracin had no effect on GNP-
induced mitochondrial depolarisation (supplementary ﬁgure
5), its effect on mitochondrial oxidation and overall cell
survival post GNP irradiation was measured (ﬁgure 3).
Bacitracin effectively inhibited GNP-induced mitochondrial
oxidation across all cell lines. DEFs for the clonogenic cell
survival curves in ﬁgure 3 are presented in table 2 along with
values corrected for the effects of bacitracin and radiation
alone. The radiosensitising effect of GNPs is completely
abrogated in MDA-MB-231 cells across all doses and sig-
niﬁcantly reduced in DU145 and T98G cells to 1.08±0.03
and 1.17±0.07 at 2 Gy respectively with bacitracin
treatment.
Discussion
Oxidative stress manifested as elevated levels of ROS fol-
lowing exposure to GNPs has been described by numerous
studies [18, 19, 22–25]. One of our previous studies showed
an effect on mitochondrial function in response to GNPs but
this was not linked to radiation response [20]. Upon obser-
vation of an oxidative cellular response involving ROS and
mitochondrial depolarisation and oxidation, it was important
to understand the impact of each event on GNP radio-
sensitisation in order to elucidate the mechanism. Using
NAC, we were able to establish that the presence of ROS had
no effect on post irradiation cell survival, with NAC treatment
ROS were still present in cells at the point of radiation,
however, GNP radiosensitisation was reduced in MDA-MB-
231 cells and entirely absent in T98G cells (supplementary
ﬁgures 4(A) and 2).
After treatment with NAC prior to GNP exposure,
mitochondrial membrane depolarisation was prevented across
all cell lines; however radiosensitisation in DU145 cells was
still observed. This suggests that mitochondrial depolarisation
is not a driver in GNP radiosensitisation. Furthermore, the
signiﬁcant increase in GNP uptake seen in DU145 cells with
NAC treatment did not result in an enhancement of radio-
sensitisation, supporting the hypothesis of a biological
mechanism in addition to a physical mechanism in radio-
sensitisation. Using different combinations of NAC and GNP
treatment, mitochondrial oxidation was prevented in both the
DU145 and T98G cell lines prior to irradiation. When mito-
chondrial oxidation was prevented, radiosensitisation was
signiﬁcantly reduced suggesting mitochondrial oxidation is a
key event in GNP radiosensitisation.
Given the overall oxidative stress response observed in
cells exposed to GNPs and the fact that these GNPs are thiol-
coated, PDI was identiﬁed as a potential driver in the overall
cellular response. PDI is an enzyme that catalyses the creation
and cleavage of disulphide bonds in folding proteins in the
Figure 3. (A) Cell survival following bacitracin and GNP treatment combined with irradiation. Cells were treated with 3 mM bacitracin for
2 h and then 500 μg ml−1 1.9 nm GNPs for 24 h, irradiated, re-seeded and left to form colonies for 7–9 d. Means are presented±standard
error of the mean. n=5. (B) Mitochondrial oxidation after combined bacitracin and GNP treatment. Mitochondrial oxidation was assessed
by Nonyl Acrdine Orange ﬂuorescent ﬂow cytometry after cells were treated with indicated concentration/incubation combinations of
bacitracin followed by 1.9 nm GNP exposure for 24 h. Means are presented±standard error of the mean. n=4. Signiﬁcance was measured
by paired t tests. *= p0.05 ,***p=0.001.
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Table 2. Dose enhancement factors. Table of DEFs with errors for cells treated with bacitracin and/or 1.9 nm GNPs at 2, 4 and 8 Gy. Numbers in bold italics are corrected for the effect of
bacitracin with radiation.
MDA-MB-231 DU145 T98G
2 Gy 4 Gy 8 Gy 2 Gy 4 Gy 8 Gy 2 Gy 4 Gy 8 Gy
Bac 0.92±0.02 1.00±0.02 1.06±0.01 1.32±0.02 1.09±0.01 0.90±0.01 1.18±0.07 1.20±0.04 1.18±0.02
Bac /1.9 nm 0.91±0.03 1.01±0.03 1.14±0.01 1.43±0.02 1.28±0.01 1.17±0.01 1.39±0.03 1.40±0.02 1.40±0.01
0.98 ± 0.04 1.04 ± 0.04 1.03 ± 0.01 1.08 ± 0.03 1.17 ± 0.01 1.30 ± 0.01 1.17 ± 0.07 1.16 ± 0.04 1.19 ± 0.01
1.9 nm 1.52±0.03 1.27±0.01 1.14±0.01 1.82±0.01 1.59±0.01 1.36±0.01 1.92±0.05 1.53±0.01 1.33±0.01
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endoplasmic reticulum (ER). It is primarily found in the ER,
however, it has been shown to be present in the nucleus,
mitochondria, cytosol and on the cell surface [26–28]. Its
expression has been linked to oncogenesis and cancer survi-
val as well as metastasis, identifying PDI as a potential
therapeutic target [29]. Its role in reducing disulphide bonds
on the cell surface and its link to mitochondrial oxidative
stress suggests PDI as a potential mediator in thiol-coated
GNP cell response. Bacitracin, an inhibitor of PDI, has been
shown to inhibit only the reductase activity of PDI and not
affect the other functions of PDI such as the oxidation and
rearrangement of disulphide bonds [30].
Within the current study, bacitracin effectively prevented
GNP-induced mitochondrial oxidation across all cells lines
(ﬁgure 3(A)). Additionally, bacitracin did not prevent GNP-
induced mitochondrial depolarisation (supplementary ﬁgure
5), supporting previous results suggesting mitochondrial
depolarisation is not a key factor in GNP radiosensitisation.
The mitochondrial depolarisation observed with bacitracin
and GNP combination treatment could be related to the role of
PDI in preventing misfolded proteins. The formation of pores
in the mitochondria membrane which cause a loss of polar-
isation have been linked to an accumulation of misfolded
proteins within the mitochondrial membrane [31]. Therefore
blocking PDI could drive this misfolded protein pore for-
mation regardless of the impact of blocking PDI on potential
biological signalling pathways.
On the whole, the results of this study allow the identi-
ﬁcation of a biological mechanism in GNP radiosensitisation.
Given the role of PDI and the thiol-coating of the GNPs, the
response is potentially a result of a thiol imbalance in the
cellular environment. The proposed mechanism of action for
the radiosensitising effect of 1.9 nm GNPs is illustrated in
ﬁgure 4. PDI–GNP interaction at the cell surface appears to
be a key driver in the sensitisation of cells to radiation. It is
possible that cell-surface PDI reduces the thiolated surface of
the GNPs, resulting in PDI oxidation which would require
reduction by glutathione. This reduction reaction would lead
to the oxidation of glutathione to glutathione disulphide.
Prolonged repetition of this process can result in depletion of
the cellular antioxidant glutathione, causing a cellular redox
imbalance and ultimately oxidative stress. The excess glu-
tathione disulphide, cellular ROS and thiolated GNPs could
react with the outer mitochondrial membrane resulting in the
formation of pores in the mitochondrial membrane and
therefore mitochondrial depolarisation. These agents can also
oxidise mitochondria however, this appears to be dependent
on cellular levels of glutathione which are enhanced by NAC
treatment. This study has shown mitochondrial oxidation to
be the most potent event in the radiosensitization of cells;
however, particularly in MDA-MB-231 cells; mitochondrial
depolarisation can also cause radiosensitization.
Disruptions in thiol metabolism have been attributed to
the radiosensitising effects of inhibiting glucose metabolism
by 2-Deoxy-D-glucose [32]. Moreover, downregulation of
glutathione has been shown to radiosensitise cells in com-
parison to stimulation of its synthesis which has been shown
to be radioprotective [33]. However, radiosensitization by the
disruption of glutathione levels and overall cellular thiol
metabolism through the activation of PDI has previously been
described. Given the potential implications of PDI in cancer,
it is possible that differential expression levels of PDI in
cancer cells could explain the ranges of radiosensitisation
observed with these GNPs.
It should also be noted that it is likely that GNP exposure
may induce other cellular stresses which can also lead to
sensitisation—as suggested by the residual sensitisation
effects seen in some cell lines when the pathway described in
this work is inhibited. This is an ongoing open research
question in the ﬁeld of nanoparticle radiosensitisation, and
this work and others highlights the need to consider all
aspects of a nanoparticle’s characteristics to understand their
sensitising properties.
The question of GNPs being radioenhancers or radio-
sensitisers is an important issue to address for their clinical
use. Despite the attractiveness of a compound which can
physically enhance radiation dose, this would be of restricted
practicality in patient treatment due to clinical radiotherapy
machines emitting in the megavoltage range and gold
absorption being most efﬁcient at dose enhancement in the
kilovoltage range. As a result, GNPs which act as biologically
driven radiosensitisers would be more applicable to clinical
scenarios, as they would be expected to maintain their sen-
sitising effects in megavoltage exposures. Additionally the
concentrations of GNPs necessary for signiﬁcant physical
dose enhancement are potentially unachievable in patients;
therefore a mechanism by which GNPs are effective in
Figure 4. Mechanism of action. Proposed mechanism of action for
the radiosensitising effect of 1.9 nm gold nanoparticles.
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combination with radiation at considerably lower concentra-
tions is more clinically relevant. A ﬁnal potential beneﬁt of
biological mechanisms of sensitisation may be improved
speciﬁcity—if GNPs can be produced which speciﬁcally
impact on pathways which are deregulated in cancer, sensi-
tisation can be obtained in tumour cells while sparing normal
tissue. Such an effect is seen in the 1.9 nm particles con-
sidered in this work, which have negligible sensitising effects
in normal ﬁbroblasts (supplementary information).
The GNPs in this study have been shown to act pre-
dominantly as radiosensitisers rather than radioenhancers.
The calculations for physical dose enhancement presume an
even distribution of the dose and GNPs throughout the cell.
Although we know the dose will not be evenly distributed,
this should only account for a minor overestimation of the
dose enhancement and cannot justify the complete lack of
radioenhancement when cells are treated with NAC or baci-
tracin. However, little is known about the effect of GNP
distribution on these calculations. Many studies including
those from our own group have found that GNPs aggregate
within the cell, primarily in endosomes. The effect of these
aggregates in terms of dose enhancement has not been
investigated but has the potential to interfere with the overall
physical effects. The discovery of this novel mechanism of
radiosensitization through the use of GNPs highlights the role
of nanotechnology in innovating research and the develop-
ment of new therapeutics. The vast catalogue of nanoparticle
combinations has the potential to signiﬁcantly add to the
knowledge of cellular mechanisms and identify novel targets
for the therapy of various diseases not only through the use of
nanoparticles as therapeutic agents themselves but also by
studying the interactions of cells with different nanoparticles.
Conclusions
The data presented in this paper clearly demonstrate a bio-
logical mechanism which contributes signiﬁcantly to the
radiosensitisation observed with 1.9 nm GNPs. Irradiation
with GNPs was shown to drive increased oxidative stress
caused by the interaction of the GNPs with the cell membrane
protein PDI, which in turn led to an overall disruption in the
thiol balance of the cell, which in turn led to signiﬁcant
increases in cell killing. The action of GNP radiosensitization
described in this paper identiﬁes a novel mechanism for the
radiosensitization of cancer cells as well as identifying new
targets for sensitising cells to radiation in the form of PDI and
the oxidation of mitochondria which could aid in the devel-
opment of new radiosensitising agents.
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